FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
Launched by WUXI HISKY MEDICAL TECHNOLOGY CO LTD · Jun 16, 2015
Trial Information
Current as of September 16, 2025
Completed
Keywords
ClinConnect Summary
The liver diseases frequently occur in China. For various reasons, the chronic liver diseases are not controlled in time, and then develop gradually into liver fibrosis and cirrhosis. Without effective treatment, the advanced liver cirrhosis seriously influences the quality of patients' life, and places an intolerable burden on family and society. At present, the scholars generally thought that the liver fibrosis at early stages is reversible. Therefore, if the liver fibrosis in patients with chronic liver diseases can be accurately evaluated at early stages and be treated in time, so we ca...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with age 18-65 years, both gender
- • Subjects with history of HBV or HBsAg positive \> 6 months up to enrollment
- • Subjects with qualified liver biopsy specimens within three months (before or after) of Fibrotouch examination for pathological staging
- • Subjects without chemical therapy history of powerful medicine to lower enzyme in the two weeks before blood biochemistry tests (e.g. dimethyl diphenyl bicarboxylate and bicyclol)
- • Subjects must agree and sign the informed consent form
- Exclusion Criteria:
- • Subjects who are unable or unwilling to sign informed consent form
- • Subjects who have merger of hepatitis C, alcohol and non-alcoholic fatty liver diseases, autoimmune liver diseases, inherited metabolic liver diseases, biliary systemic diseases or liver and gall parasitic diseases
- • Subjects who have other serious chronic disorders or history of malignancy
- • Subjects with ALT ≥5 ULN in the past 1 month
- • Subjects with WBC\<3.5×10\^9/L, PLT\<60×10\^9/L, PTA\<60%
- • Subjects with DBIL≥1.5 ULN
- • Subjects with decompensated cirrhosis (especially the people with ascites)
- • Pregnant or lactating women, or women who has a pregnant plan and don't want to birth control in the study period
- • Subjects who have wound on the right upper abdomen recently
- • Subjects who have various space-occupying tumor or cyst in right liver
- • Subjects who have none or limited legal capacity
About Wuxi Hisky Medical Technology Co Ltd
WuXi Hisky Medical Technology Co., Ltd. is a leading clinical trial sponsor dedicated to advancing innovative healthcare solutions through cutting-edge medical technologies. With a strong emphasis on research and development, WuXi Hisky specializes in the design and execution of clinical trials that adhere to the highest regulatory standards. The company leverages its extensive expertise and state-of-the-art facilities to support pharmaceutical and biotechnology partners in bringing new therapies to market efficiently and effectively. Committed to enhancing patient outcomes, WuXi Hisky fosters collaborations that drive scientific progress and improve the quality of life globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, China
Tianjin, China
Zhengzhou, China
Shanghai, China
Beijing, China
Beijing, China
Beijing, China
Changchun, China
Chongqing, China
Guangzhou, China
Nanjing, China
Shanghai, China
Shijiazhuang, China
Urumqi, China
Xi'an, China
Patients applied
Trial Officials
Jidong JIA, MD
Study Chair
Beijing Friendship Hospital
Jianbiao CAO, MD
Principal Investigator
The Military General Hospital of Beijing, PLA
Qing MAO, MD
Principal Investigator
The First Affiliated Hospital, Third Military University
Ying HAN, MD
Principal Investigator
The First Affiliated Hospital of the Fourth Military Medical University
Junqi NIU, MD
Principal Investigator
The First Hospital of Jilin University
Yuemin NAN, MD
Principal Investigator
Hebei Medical University Third Hospital
JIA SHANG, MD
Principal Investigator
Henan Provincial People's Hospital
Jun LI, MD
Principal Investigator
Jiangsu Provincial People's Hospital
Qing XIE, MD
Principal Investigator
Ruijin Hospital
Hong TANG, MD
Principal Investigator
West China Hospital
Tao HAN, MD
Principal Investigator
Tianjin Third Central Hospital
Qingchun FU, MD
Principal Investigator
No.85 Hospital, Changning, Shanghai, China
Zhiliang GAO, MD
Principal Investigator
Third Affiliated Hospital, Sun Yat-Sen University
Xiaozhong WANG, MD
Principal Investigator
Hospital of Chinese Medicine of the Xinjiang Uygur Autonomous Region
Anlin MA, MD
Principal Investigator
The China-Japan Friendship Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials